期刊文献+

Ki-67对腋窝淋巴结阳性的乳腺癌全乳腺切除术后的预后价值 被引量:3

Prognostic value of Ki-67 in axillary lymph node-positive breast cancer after mastectomy
暂未订购
导出
摘要 目的:探讨Ki-67对腋窝淋巴结阳性的乳腺癌全乳腺切除术后患者的预后价值。方法:回顾性分析2002年4月至2007年12月收治的可手术的腋窝淋巴结阳性乳腺癌患者454例。用Kaplan-Meier法计算生存率,Logrank法和Cox模型分别进行单因素和多因素预后分析。结果:Ki-67表达与病理分级、Her-2、p53的表达呈正相关,与ER、PR的表达呈负相关,与淋巴结转移状态、T分期等无相关性。对全组患者进行预后分析,未发现Ki-67对预后有影响。亚组分析发现对于腋窝淋巴结1-3个转移的患者,Ki-67为影响远处转移(P=0.006)和总体生存(P<0.001)的预后因素,多因素分析提示Ki-67为影响远处转移(P=0.011)和总体生存(P=0.003)的独立危险因素。而腋窝淋巴结≥4个转移的患者Ki-67则不影响预后(P均>0.05)。结论:Ki-67可做为腋窝淋巴结阳性乳腺癌患者的预后因素之一,特别是对于腋窝淋巴结1-3个转移的患者。 Objective:To investigate the prognostic value of Ki-67 in axillary lymph node-positive breast cancer after mastectomy.Methods:For the retrospective data of 454 eligible patients between April 2002 to December 2007,survival analysis were performed using the Kaplan-Meier method.Univariate and multivariate analyses were performed using the Log-rank method and Cox regression.Results:High Ki-67 expression was positively significantly correlated with pathological grade,Her-2,p53 expression,and was negatively correlated with ER and PR(P all 0.05).Not found high Ki-67 expression correlated with nodal involvement and larger tumor sizes.High Ki-67 expression was not impact the prognosis in entire cohort.In the subgroup analysis,patients with 1-3 positive lymph nodes,Ki-67 was an prognostic factor for metastasis-free survival(MFS)(P=0.006) and overall survival(OS)(P0.001) in univariate analysis,Ki-67 was not affect prognosis in patients with 4 or more positive lymph nodes(P0.05).Multivariate analysis showed that for 1-3 positive lymph nodes,Ki-67 was an independent risk factor in MFS(P=0.011) and OS(P=0.003).Conclusion:High Ki-67 expression indicates an unfavorable prognosis impact for MFS and OS in breast cancer patients with axillary lymph node-positive,especially for patients with 1-3 positive lymph nodes.
出处 《现代肿瘤医学》 CAS 2013年第7期1503-1507,共5页 Journal of Modern Oncology
基金 广东省科技计划社会发展项目(编号:2008B060600019)
关键词 乳腺癌 KI-67 预后 全乳腺切除术 breast cancer Ki-67 prognosis mastectomy
  • 相关文献

参考文献22

  • 1Scholzen T,Gerdes J.The Ki-67 protein: from the known and the unknown[J].J Cell Physiol,2000,182(3):311-322.
  • 2Goldhirsch A,Ingle JN,Gelber RD,et al.Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009[J].Ann Oncol,2009,20(8):1319-1329.
  • 3Goldhirsch A,Wood WC,Coates AS,et al.Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St.Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011[J].Ann Oncol,2011,22(8):1736-1747.
  • 4De Azambuja E,Cardoso F,de Castro G Jr,et al.Ki-67 as prognostic marker in early breast cancer: a meta-analysisof published studies involving 12,155 patients[J].Br J Cancer,2007,96(10):1504-1513.
  • 5Stuart-Harris R,Caldas C,Pinder SE,et al.Proliferation markers and survival in early breast cancer: a systematic review and meta-analysis of 85 studies in 32,825 patients[J].Breast,2008,17(4): 323-334.
  • 6Urruticoechea A,Smith IE,Dowsett M.Proliferation marker Ki-67 in early breast cancer[J].J Clin Oncol,2005,23(28):7212-7220.
  • 7Neri A,Marrelli D,Pedrazzani C,et al.Prognostic relevance of proliferative activity evaluated by mib-1 immunostaining in node negative breast cancer[J].Eur J Surg Oncol,2008,34(12):1299-1303.
  • 8Jalava P,Kuopio T,Juntti-Patinen L,et al.Ki-67 immunohistochemistry: A valuable marker in prognostication but also a risk of misclassification.Proliferation subgroups based on Ki-67 fraction and standardized mitotic index[J].Histopathology,2006,48(6):674-682.
  • 9Sayer HG,Kath R,Kliche KO,et al.Premenopausal breast cancer: chemotherapy and endocrine therapy[J].Drugs,2002,62(14): 2025-2038.
  • 10Kelleher M,Miles D.The adjuvant treatment of breast cancer[J].Int J Clin Pract,2003,57(3):195-199.

同被引文献17

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部